As filed with the United States Securities and Exchange Commission on April 13, 2018 333-188759

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

POST-EFFECTIVE AMENDMENT NO. 1 TO FORM F-6
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933 FOR AMERICAN DEPOSITARY SHARES EVIDENCED BY
AMERICAN DEPOSITARY RECEIPTS

 

Genmab A/S

(Exact name of issuer of deposited securities as specified in its charter)

 

N/A
(Translation of issuer’s name into English)

 

Denmark

(Jurisdiction of incorporation or organization of issuer)

 

DEUTSCHE BANK TRUST COMPANY AMERICAS
(Exact name of depositary as specified in its charter )

 

60 Wall Street
New York, New York 10005
(212) 250-9100

(Address, including zip code, and telephone number, including area code, of depositary’s principal executive offices)

 

Genmab US, Inc.

902 Carnegie Center, Suite 301

Princeton, NJ 08540, USA

(609) 430 2481

(Address, including zip code, and telephone number, including area code, of agent for service)

 

Copies to:

 

Deutsche Bank Trust Company Americas

60 Wall Street
New York, New York 10005
(212) 250-9100

 

It is proposed that this filing become effective under Rule 466

 

  immediately upon filing

on ___at ___ a.m. (EST)

  

If a separate registration statement has been filed to register the deposited shares, check the following box. ☐

 

CALCULATION OF REGISTRATION FEE

 

Title of Each Class of
Securities to be Registered
Amount to be
Registered
Proposed Maximum
Aggregate Price Per Unit*
Proposed Maximum
Aggregate Offering Price**
Amount of
Registration Fee
American Depositary Shares evidenced by American Depositary Receipts, each American Depositary Share representing one-tenth of one  ordinary share of Genmab A/S

n/a

 

n/a n/a n/a

*        Each unit represents one American Depositary Share. 

**      Estimated solely for the purpose of calculating the registration fee. Pursuant to Rule 457(k), such estimate is computed on the basis of the maximum aggregate fees or charges to be imposed in connection with the issuance of receipts evidencing American Depositary Shares.

 

 

 

 

 

 

This Post-Effective Amendment to Registration Statement on Form F-6 may be executed in any number of counterparts, each of which shall be deemed an original, and all of such counterparts together shall constitute one and the same instrument.

 

 

 

 

 

PART I
INFORMATION REQUIRED IN PROSPECTUS

 

PROSPECTUS

 

The prospectus consists of the proposed form of American Depositary Receipt, included as Exhibit A to the form of Amendment No. 1 to the Deposit Agreement filed as Exhibit (a)(2) to this Post-Effective Amendment to Registration Statement on Form F-6 and incorporated herein by reference.

 

Item 1. DESCRIPTION OF SECURITIES TO BE REGISTERED

 

CROSS REFERENCE SHEET

 

Item Number and Caption  

Location in Form of American

Depositary Receipt (“Receipt”)
Filed Herewith as Prospectus

     
1. Name of depositary and address of its principal executive office   Face of Receipt, Introductory article and bottom center
       
2.

Title of Receipts and identity of deposited securities  

  Face of Receipt, Top center
         
  Terms of Deposit:    
         
  (i) The amount of deposited securities represented by one American Depositary Share   Face of Receipt, Upper right corner
         
  (ii) The procedure for voting, if any, the deposited securities   Paragraph (15)
         
  (iii) The collection and distribution of dividends   Paragraph (13)
         
  (iv) The transmission of notices, reports and proxy soliciting material   Paragraphs (12), (14) and (15)
         
  (v) The sale or exercise of rights   Paragraphs (2), (6), (13), (16) and (21)
         
  (vi) The deposit or sale of securities resulting from dividends, splits or plans of reorganization   Paragraphs (13) and (16)                     
         
  (vii) Amendment, extension or termination of the deposit arrangements   Paragraphs (20) and (21) (no provision for extensions)
         
  (viii) Rights of holders of Receipts to inspect the transfer books of the depositary and the list of holders of Receipts   Paragraph (12)
         
  (ix) Restrictions upon the right to deposit or withdraw the underlying securities   Paragraphs (2), (3) and (4)

 

 

 

 

         
  (x) Limitation upon the liability of the depositary   Paragraphs (6), (10), (15), (16), (17), (18) and (21)
         
3. Fees and charges which may be imposed directly or indirectly against holders of Receipts   Paragraph (9)

 

 

I tem 2.       AVAILABLE INFORMATION   Paragraph (12)

 

(a) As set forth in Paragraph (12) of the Form of Receipt constituting the prospectus included herein, Genmab A/S publishes information in English required to maintain the exemption from registration under Rule 12g3-2(b) under the Securities Exchange Act of 1934, as amended (the "Securities Exchange Act of 1934") on its Internet Web site (http://www.genmab.com) or through an electronic information delivery system generally available to the public in its primary trading market.

 

PART II
INFORMATION NOT REQUIRED IN PROSPECTUS

 

Item 3. EXHIBITS

 

(a)(1) Form of Deposit Agreement, dated as of              , 2013, by and among Genmab A/S, Deutsche Bank Trust Company Americas, as depositary (the “ Depositary ”), and all Holders and Beneficial Owners from time to time of American Depositary Shares evidenced by American Depositary Receipts issued thereunder. Previously filed.

 

(a)(2) Form of Amendment to Deposit Agreement (including the form of American Depositary Receipt to be issued thereunder, attached as Exhibit A thereto). – Filed herewith as Exhibit (a)(2).

 

(b) Any other agreement to which the Depositary is a party relating to the issuance of the American Depositary Shares registered hereunder or the custody of the deposited securities represented thereby. – Not Applicable.

 

(c) Every material contract relating to the deposited securities between the Depositary and the Company in effect at any time within the last three years. – Not Applicable.

 

(d) Opinion of counsel to the Depositary as to the legality of the securities being registered. – Previously filed.

 

(e) Certification under Rule 466. – Filed herewith as Exhibit (e).

 

(f) Powers of Attorney for certain officers and directors and the authorized representative of the Company. – Set forth on the signature pages hereto.

 

 

 

 

Item 4. UNDERTAKINGS

 

(a) The Depositary hereby undertakes to make available at the principal office of the Depositary in the United States, for inspection by holders of the American Depositary Receipts, any reports and communications received from the issuer of the deposited securities which are both (1) received by the Depositary as the holder of the deposited securities; and (2) made generally available to the holders of the underlying securities by the issuer.

 

(b) If the amounts of fees charged are not disclosed in the prospectus, the Depositary undertakes to prepare a separate document stating the amount of any fee charged and describing the service for which it is charged and to deliver promptly a copy of such fee schedule without charge to anyone upon request. The Depositary undertakes to notify each registered holder of an American Depositary Receipt 30 days before any change in the fee schedule.

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Act of 1933, as amended, Deutsche Bank Trust Company Americas, on behalf of the legal entity created by the Deposit Agreement, by and among Genmab A/S, Deutsche Bank Trust Company Americas, as depositary, and all Holders from time to time of American Depositary Shares evidenced by American Depositary Receipts issued thereunder, certifies that it has reasonable grounds to believe that all the requirements for filing on Form F-6 are met and has duly caused this Post-Effective Amendment to Registration Statement on Form F-6 to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of New York, State of New York, on April 13, 2018.

 

 

Legal entity created by the Deposit Agreement for the issuance of American Depositary Receipts evidencing American Depositary Shares, each representing one-tenth of one ordinary share of Genmab A/S.

 

Deutsche Bank Trust Company Americas, solely in its capacity as Depositary

     
     
  By: /s/ Michael Curran
  Name: Michael Curran
  Title: Vice President
     
  By: /s/ Michael Fitzpatrick
  Name: Michael Fitzpatrick
  Title: Vice President

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Act of 1933, as amended, Genmab A/S certifies that it has reasonable grounds to believe that all the requirements for filing on Form F-6 are met and has duly caused this Post-Effective Amendment to Registration Statement on Form F-6 to be signed on its behalf by the undersigned, thereunto duly authorized, in the Kingdom of Denmark on April 13, 2018.

 

  Genmab A/S
     
  By: /s/ Prof. Jan G. J. van de Winkel, Ph.D.
  Name:   Prof. Jan G. J. van de Winkel, Ph.D.
  Title: President and Chief Executive Officer

 

Know all persons by these presents that each person whose signature appears below constitutes and appoints Prof. Jan G. J. van de Winkel, Ph.D. and David A. Eatwell, jointly and severally, his or her true lawful attorneys-in-fact and agents with full and several power of substitution and resubstitution for and in his or her name, place and stead, in any and all capacities, to sign any and all amendments, including post-effective amendments and supplements to this Registration Statement and any registration statements pursuant to Rule 462(b) under the Securities Act of 1933, as amended, relating thereto, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as they or he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

 

 

 

 

Pursuant to the requirements of the Securities Act of 1933, as amended, this Post-Effective Amendment to Registration Statement on Form F-6 has been signed by the following persons in the capacities indicated on April 13, 2018.

 

Signature

 

Title

   

/s/ Mats Pettersson  

 

Chairman

Mats Pettersson    
     

/s/ Anders Gersel Pedersen, M.D., Ph.D.  

 

Deputy Chairman

Anders Gersel Pedersen, M.D., Ph.D.    
     

/s/ Prof. Jan G. J. van de Winkel, Ph.D.  

 

President and Chief Executive Officer

Prof. Jan G. J. van de Winkel, Ph.D.    
     

/s/ David A. Eatwell  

 

Chief Financial Officer and Authorized Representative in the United States

David A. Eatwell    
     

/s/ Deirdre P. Connelly  

 

Director

Deirdre P. Connelly    
     

/s/ Pernille Erenbjerg  

 

Director

Pernille Erenbjerg    
     

/s/ Paolo Paoletti, M.D.  

 

Director

Paolo Paoletti, M.D.    
     

/s/ Peter Storm Kristensen  

 

Director

Peter Storm Kristensen    
     

/s/ Rolf Hoffmann  

 

Director

Rolf Hoffmann    
     

/s/ Rick Hibbert, MBA, Ph.D.  

 

Director

Rick Hibbert, MBA, Ph.D.    
     

/s/ Daniel J. Bruno  

 

Director

Daniel J. Bruno    

 

 

 

 

INDEX TO EXHIBITS

 

Exhibit Number  

 

(a)(2) Form of Amendment No. 1 to Deposit Agreement

 

(e) Rule 466 Certification

 

 

Genmab A S (PK) (USOTC:GNMSF)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Genmab A S (PK) Charts.
Genmab A S (PK) (USOTC:GNMSF)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Genmab A S (PK) Charts.